RNA-based therapeutics are gaining traction due to advancements in delivery technologies, despite historical challenges with ...

In a legal battle between BioNTech and CureVac, the European Patent Office declared a patent owned by CureVac ...

As part of the Fast Track designation, Sanofi is set to launch a Phase I/II trial to evaluate the immunogenicity and safety of its novel mRNA vaccine in preventing chlamydia.

Two molecular control factors play a decisive role in what is known as splicing, the cutting and assembly of mature messenger ...

Cancer refers to a group of complicated diseases which is one of the top two leading causes of death globally. Traditional chemotherapy and radiation ...

As vaccine sentiment fluctuates and political scrutiny increases, Yale researchers weigh in on scientific transparency, ...

The European Patent Office declared a patent owned by CureVac , valid, after a challenge from drugmaker BioNTech , the company said on Thursday.

The shocking rise of aggressive cancers post-COVID-19 is prompting concerns from health experts about the long-term consequences of mRNA vaccines. One of the world's leading oncologists, Dr. Patrick ...

We recently published a list of Did Jim Cramer Nail or Miss These 14 Stocks? In this article, we are going to take a look at ...

Cronin has worked at Moderna since 2021, when she was brought on to market the biotech company’s COVID-19 vaccine.

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $25.0 to $70.0 for Moderna over the recent three months. In terms of liquidity ...

We recently published a list of 10 Stocks To Trade Without Tariffs And Interest Rate Fears. In this article, we are going to ...